Allison L Naleway1, Brad Crane2, Ning Smith2, Matthew F Daley3, James Donahue4, Julianne Gee5, Sharon K Greene6, Theresa Harrington5, Lisa A Jackson7, Nicola P Klein8, Hung Fu Tseng9, Claudia Vellozzi5, Eric S Weintraub5. 1. Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA. Electronic address: allison.naleway@kpchr.org. 2. Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA. 3. Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, USA. 4. Marshfield Clinic Research Foundation, Marshfield, WI, USA. 5. Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA, USA. 6. Harvard Pilgrim Health Care Institute and Department of Population Medicine, Harvard Medical School, Boston, MA, USA. 7. Group Health Research Institute, Seattle, WA, USA. 8. Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA. 9. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
Abstract
BACKGROUND: To investigate concerns about a potential association between quadrivalent human papillomavirus vaccination (HPV4) and venous thromboembolism (VTE), we conducted a self-controlled case series study in adolescents and young adults 9-26 years of age in the Vaccine Safety Datalink. METHODS: We identified potential VTE cases diagnosed in 2008 through 2011 who had also received at least one HPV4 dose during that period. We confirmed each presumptive diagnosis by medical record review. We calculated incidence rate ratios (IRRs) and 95% confidence intervals (CI) to estimate the risk in the 1-60 day period following HPV4 exposure and in subsets of that period. IRRs were stratified by age, gender, hormonal contraceptive use, and recent surgery or trauma. RESULTS: We identified 313 potential cases of VTE among HPV4 vaccinees, and 291 (93%) had sufficient medical records for review. Of these, we confirmed 156 (54%) cases. VTE was uncommon among males (n=3) and 9-12 year olds (n=4). Nearly all confirmed cases (97%) had at least one known risk factor for VTE, including hormonal contraceptive use, obesity, and hypercoagulability. Sixteen (10%) confirmed cases occurred in the 1-60 days following HPV4 exposure. The risk of VTE varied from 1.47 (95% CI: 0.47-4.64) in the 1-7 days following HPV4 exposure to 0.92 (95% CI: 0.54-1.57) in the 1-60 days following vaccination. It was not possible to calculate a stratified IRR for males due to small sample size; the other risk factors evaluated did not significantly affect the risk of VTE after HPV4 exposure. CONCLUSION: The risk of developing VTE among 9- to 26-year-olds was not elevated following HPV4 exposure. Sample size limited our ability to rigorously evaluate potential effect modifiers, such as gender, through stratified analysis.
BACKGROUND: To investigate concerns about a potential association between quadrivalent human papillomavirus vaccination (HPV4) and venous thromboembolism (VTE), we conducted a self-controlled case series study in adolescents and young adults 9-26 years of age in the Vaccine Safety Datalink. METHODS: We identified potential VTE cases diagnosed in 2008 through 2011 who had also received at least one HPV4 dose during that period. We confirmed each presumptive diagnosis by medical record review. We calculated incidence rate ratios (IRRs) and 95% confidence intervals (CI) to estimate the risk in the 1-60 day period following HPV4 exposure and in subsets of that period. IRRs were stratified by age, gender, hormonal contraceptive use, and recent surgery or trauma. RESULTS: We identified 313 potential cases of VTE among HPV4 vaccinees, and 291 (93%) had sufficient medical records for review. Of these, we confirmed 156 (54%) cases. VTE was uncommon among males (n=3) and 9-12 year olds (n=4). Nearly all confirmed cases (97%) had at least one known risk factor for VTE, including hormonal contraceptive use, obesity, and hypercoagulability. Sixteen (10%) confirmed cases occurred in the 1-60 days following HPV4 exposure. The risk of VTE varied from 1.47 (95% CI: 0.47-4.64) in the 1-7 days following HPV4 exposure to 0.92 (95% CI: 0.54-1.57) in the 1-60 days following vaccination. It was not possible to calculate a stratified IRR for males due to small sample size; the other risk factors evaluated did not significantly affect the risk of VTE after HPV4 exposure. CONCLUSION: The risk of developing VTE among 9- to 26-year-olds was not elevated following HPV4 exposure. Sample size limited our ability to rigorously evaluate potential effect modifiers, such as gender, through stratified analysis.
Authors: Nicola P Klein; John Hansen; Chun Chao; Christine Velicer; Michael Emery; Jeff Slezak; Ned Lewis; Kamala Deosaransingh; Lina Sy; Bradley Ackerson; T Craig Cheetham; Kai-Li Liaw; Harpreet Takhar; Steven J Jacobsen Journal: Arch Pediatr Adolesc Med Date: 2012-12
Authors: Richard H White; Martina Garcia; Banafsheh Sadeghi; Daniel J Tancredi; Patricia Zrelak; Joanne Cuny; Pradeep Sama; Harriet Gammon; Stephen Schmaltz; Patrick S Romano Journal: Thromb Res Date: 2010-04-28 Impact factor: 3.944
Authors: Julianne Gee; Allison Naleway; Irene Shui; James Baggs; Ruihua Yin; Rong Li; Martin Kulldorff; Edwin Lewis; Bruce Fireman; Matthew F Daley; Nicola P Klein; Eric S Weintraub Journal: Vaccine Date: 2011-09-09 Impact factor: 3.641
Authors: James Baggs; Julianne Gee; Edwin Lewis; Gabrielle Fowler; Patti Benson; Tracy Lieu; Allison Naleway; Nicola P Klein; Roger Baxter; Edward Belongia; Jason Glanz; Simon J Hambidge; Steven J Jacobsen; Lisa Jackson; Jim Nordin; Eric Weintraub Journal: Pediatrics Date: 2011-04-18 Impact factor: 7.124
Authors: Barbara A Slade; Laura Leidel; Claudia Vellozzi; Emily Jane Woo; Wei Hua; Andrea Sutherland; Hector S Izurieta; Robert Ball; Nancy Miller; M Miles Braun; Lauri E Markowitz; John Iskander Journal: JAMA Date: 2009-08-19 Impact factor: 56.272
Authors: Sheree L Boulet; Scott D Grosse; Courtney D Thornburg; Hussain Yusuf; James Tsai; W Craig Hooper Journal: Pediatrics Date: 2012-09-17 Impact factor: 7.124
Authors: Allison L Naleway; Rachel Gold; Samantha Kurosky; Karen Riedlinger; Michelle L Henninger; James D Nordin; Elyse O Kharbanda; Stephanie Irving; T Craig Cheetham; Natalie L McCarthy Journal: Vaccine Date: 2013-04-30 Impact factor: 3.641
Authors: James G Donahue; Burney A Kieke; Edwin M Lewis; Eric S Weintraub; Kayla E Hanson; David L McClure; Elizabeth R Vickers; Julianne Gee; Matthew F Daley; Frank DeStefano; Rulin C Hechter; Lisa A Jackson; Nicola P Klein; Allison L Naleway; Jennifer C Nelson; Edward A Belongia Journal: Pediatrics Date: 2019-11-18 Impact factor: 7.124
Authors: W Katherine Yih; Judith C Maro; Michael Nguyen; Meghan A Baker; Carolyn Balsbaugh; David V Cole; Inna Dashevsky; Adamma Mba-Jonas; Martin Kulldorff Journal: Am J Epidemiol Date: 2018-06-01 Impact factor: 4.897
Authors: Kandace L Amend; Bruce Turnbull; Li Zhou; Morgan A Marks; Christine Velicer; Patricia Saddier; John D Seeger Journal: Hum Vaccin Immunother Date: 2022-06-17 Impact factor: 4.526